Monitor for partnering announcements or additional preclinical/clinical data that could validate the mechanism in humans. The $3M market cap implies binary risk: a partnership could drive significant upside, but failure to replicate in humans or secure a deal would likely lead to further declines.
Price Chart
Executive Summary
Artelo Biosciences announced nonclinical results showing its oral dual cannabinoid agonist ART27.13 produced ~20% weight loss in obese mice (comparable to semaglutide) and ~40% weight loss when combined with semaglutide (double either agent alone). The data challenge the long-held CB1-antagonist dogma and suggest a differentiated, complementary mechanism to GLP-1s, but remain preclinical — the company has no approved products and a $3M market cap.
Key Facts
- ART27.13 monotherapy reduced body weight ~20% in obese mice over 4 weeks, matching semaglutide.
- Combination of ART27.13 + semaglutide produced ~40% weight loss, double either agent alone.
- Weight loss was predominantly fat (~80% of total loss for ART27.13 groups vs ~70% for semaglutide).
- ART27.13 had no effect on body weight or composition in lean mice on a standard diet.
- ART27.13 is a peripherally selective dual CB1/CB2 agonist, initially developed by AstraZeneca, with prior Phase 2 data in cancer cachexia (CAReS) showing +6% weight gain vs -5% on placebo.
Financial Impact
No financial data provided; company is pre-revenue with $3M market cap. J.P. Morgan projects global GLP-1 market could reach $200B by 2030, but Artelo's ability to capture value is highly uncertain.
Risk Factors
- Preclinical results may not translate to human clinical trials; prior animal data often fails to replicate in humans.
- Company has no approved products, minimal revenue, and a $3M market cap — financing risk is high.
- Highly competitive GLP-1/obesity market dominated by Novo Nordisk, Eli Lilly, and others; ART27.13 is years behind.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3363068 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $3.11 | awaiting T+60 | — | $2.20 (+29.26%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.20 (−41.33%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.20 (−67.79%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.20 (+109.52%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.20 (−98.20%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.20 (−50.68%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.20 (+61.76%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.20 (+50.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers